Ro-3306

Research use only, not for human use.

Ro-3306 is a potent, selective, ATP-competitive CDK1 inhibitor with Ki of 35 nM against CDK1/cyclin B1, 10-fold selectivity relative to CDK2/cyclin E and >50-fold relative to CDK4/cyclin D.

Ro-3306 is a potent, selective, ATP-competitive CDK1 inhibitor with Ki of 35 nM against CDK1/cyclin B1, 10-fold selectivity relative to CDK2/cyclin E and >50-fold relative to CDK4/cyclin D; also inhibits CDK1/cyclin A complexes with Ki of 110 nM, shows >15-fold selectivity against a diverse panel of 8 human kinases; reversibly arrests human cells at the G(2)/M border of the cell cycle and allows for effective cell synchronization in early mitosis; enhances p53-mediated Bax activation and mitochondrial apoptosis in AML.

Ro3306

Angiogenesis

CDK

CDK1;ERK;PKA;PKCδ;SGK

Cancer

——

872573-93-8

351.45

C18H13N3OS2

>98% (HPLC)

DMSO: ≥ 47 mg/mL

O=C1N=C(NCC2=CC=CS2)S/C1=C/C3=CC=C4N=CC=CC4=C3

4(5H)-Thiazolone, 5-(6-quinolinylmethylene)-2-[(2-thienylmethyl)amino]-, (5Z)-

(-20℃)

With Ice Pack

≥ 2 years